REG - Immupharma PLC - Audited Report & Accounts published on website

ImmuPharmaAnnouncement

30/04/2020 10:00

RNS Number : 4797L
  
Immupharma PLC
  
30 April 2020
  
 

RNS: RELEASE                                                                                                                                             30 April 2020
 
 
ImmuPharma PLC
("ImmuPharma" or the "Company")
 
Audited Report & Accounts published on website
 
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Audited Annual Report and Accounts ("Report") for the year ended 31 December 2019, has today been published on the Company's website. Copies of this Report, including the Notice of Annual General Meeting, will be posted to shareholders in the near future.
 
Confirmation of this date will be announced to the market on the day of posting. To view the Report please go to: www.immupharma.co.uk.
 




 
For further information please contact:
 




ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman


+ 44 (0) 207 152 4080




Dimitri Dimitriou, Chief Executive Officer


 




Lisa Baderoon, Head of Investor Relations
 


+ 44 (0) 7721 413496
 
 




SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
 
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes
 
SI Capital (Joint Broker)
Nick Emerson
 


+44 (0) 203 368 8974
 
 
+44 (0) 203 815 8880
 
 
+44 (0) 1483 413500
 
 




4Reliance (Euronext Growth Listing Sponsor)
Jean-Charles Snoy
 
Degroof Petercam (Liquidity Provider)
Erik De Clippel
 
Backstage Communication
Olivier Duquaine
Gunther De Backer


+32 (0) 2 747 02 60
 
 
+32 (0) 2 287 95 34
 
 
 
+32 (0) 477 504 784
+32 (0) 475 903 909
 




 


 




 




 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ACSIMMPTMTAJMJM